The heart drug digoxin could potentially be combined with existing cancer therapies to prevent the spread of tumors, an early trial suggests. But questions remain.

The team reported on the study results in Nature Medicine, in a paper titled, “Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial ...

Digoxin blocks these ion pumps and thus suppresses the ion exchange. The cells therefore absorb more calcium from the outside of the cell membrane. This weakens the cohesion of the cancer cells in ...

One of cancer’s deadliest tricks is its ability to spread to other organs. An existing cardiac drug has now been found to reduce the risk of metastasis by dissolving circulating clusters of breast ...

When the heart skips a beat: research from discovery science through to benefits for patients and the NHS. Throughout the ...

A study from the University of Birmingham, UK, has indicated that the use of digoxin could lead to substantial cost savings for the National Health Service (NHS) when treating senior individuals with ...

Using a most cost-effective drug to treat some of the most common and dangerous heart conditions could save the NHS a considerable amount of money ...

First used in 1785, this century-old medication is now emerging as a modern solution with significant healthcare benefits ...

A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating older patients with atrial fibrillation and heart failure. This was ...

The active ingredient digoxin, a substance found in foxglove, reduces the number of cells in clusters of breast cancer cells circulating in the blood. These clusters are responsible for the formation ...

In a clinical study, the researchers administered the drug digoxin at a low and safe dosage for one week to nine patients with metastatic breast cancer. The result: the number of cells per cluster ...